NY-GLENFARNE-GROUP
Glenfarne Group, LLC (“Glenfarne”), owner of the Federal Energy Regulatory Commission (“FERC”) permitted Magnolia LNG and Texas LNG facilities, supports the collaboration of the world’s political and business leaders to create a global infrastructure strategy to ensure the world’s energy security in Europe and emerging markets, while accelerating a reliable path forward for the energy transition.
Recent events in Europe stemming from Russia’s invasion of Ukraine and the resulting energy crisis have demonstrated the critical nature of global energy security. Glenfarne reiterates its support for Ukraine and its people and is stepping up its commitment by accelerating efforts to deliver responsibly sourced, environmentally sensible U.S. liquefied natural gas (“LNG”) to commercial partners in Europe.
“At Glenfarne, we believe the world won’t have an accelerated energy transition without energy security. Energy security is therefore a key factor in mitigating the impacts of climate change as well as enhancing the prosperity of economies globally. Governments, development and infrastructure banks, and energy companies need to work together to ensure that no war, conflict, or other threat leaves a continent and the rest of the world at risk of unstable energy supply,” said Brendan Duval, Founder and CEO of Glenfarne Group, LLC.
Vlad Bluzer, Managing Director of Magnolia LNG and Texas LNG, said, “As a Ukrainian, it pains me to see the invasion of a peaceful European nation and disruption of the lives of so many people. I am grateful to be part of the solution helping the European continent achieve energy independence for decades to come by facilitating long term deliveries of responsibly sourced U.S. LNG. These deliveries of LNG can fortify the European continent’s energy stability, and incentivize like-minded governments, banks, and global corporate citizens to invest together to ensure energy security and hasten the energy transition.”
Glenfarne’s FID on its LNG facilities will introduce new LNG capacity into the global market at a time when significant volumes are needed to shore up the increased demand from Europe and Asia. With both LNG facilities, together with its existing grid stability, renewables, and other natural gas infrastructure assets, Glenfarne is committed to energy transition investment that helps grow economies throughout the world.
About Glenfarne Group, LLC
Glenfarne is a privately held energy and infrastructure development and management firm based in New York City and Houston, Texas with offices in Dallas, Texas; Panama City, Panama; Santiago, Chile; Bogota, Colombia; Florianopolis, Brazil; Seoul, South Korea; and Ho Chi Minh City, Vietnam. Glenfarne’s seasoned executives, asset managers, and operators develop, acquire, manage, and operate energy infrastructure assets throughout North and South America and Asia. For more information, please visit www.GlenfarneGroup.com .
About Magnolia LNG
Magnolia LNG is an 8.8 mtpa modularized liquefaction and export facility that is located in the heart of Louisiana’s vast natural gas corridor on the Calcasieu Ship Channel near Lake Charles. It is adjacent to the existing Kinder Morgan Louisiana Pipeline, through which all of its feed gas will be transported. Magnolia LNG is fully permitted by FERC and has both FTA and non-FTA export authorizations from the DOE.
Magnolia LNG will utilize the patented OSMR® liquefaction technology, a low-cost, highly efficient process designed to generate 30 percent lower greenhouse gas (GHG) emissions than other conventional LNG processes.
About Texas LNG
Texas LNG is a 4 mtpa modularized liquefaction export facility that is located in South Texas on the Port of Brownsville’s deep water ship channel with pipeline access to the vast Permian and Eagle Ford gas basins. It is fully permitted by FERC and has both FTA and non-FTA export authorizations from the DOE.
Glenfarne is the majority owner of Texas LNG, and Samsung Engineering Co., Ltd. is an indirect minority equity owner and strategic partner to Texas LNG.
Additional information about Texas LNG may be found on its website at www.txlng.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220314005571/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Dompé Doses First Patients in Europe and US in Phase 3 Studyof Isocyclosporin for Atopic Keratoconjunctivitis16.12.2025 13:00:00 CET | Press release
Atopic keratoconjunctivitis(AKC) is a chronic inflammatory disease of the eye that is frequently associated with atopic conditions, and limited disease awareness often leads to delayed or missed diagnosis. Isocyclosporin is a novel, dual inhibitor oftwo critical immunepathways in ocular inflammation like AKC. Dompé, a leading biopharmaceutical company with operations in Italy and the U.S., announced the first patients have been enrolled in a Phase 3 study of Isocyclosporin for the treatment of atopic keratoconjunctivitis (AKC). Isocyclosporin is a dual inhibitor of transient receptor potential (TRP) cation channel, mucolipin subfamily, member 2 (TRPML2) and calcineurin, key regulators of immune and inflammatory response in chronic inflammatory eye diseases. The Phase 3 trial is a multicenter, randomized, double-masked study comparing isocyclosporin against vehicle control in improving ocular signs and symptoms after six weeks of treatment. “This milestone underscores Dompé’s commitment
Visa Launches Stablecoin Settlement in the United States, Marking a Breakthrough for Stablecoin Integration16.12.2025 13:00:00 CET | Press release
With more than $3.5B in annualized stablecoin settlement volume1, Visa brings USDC settlement to U.S. institutions. Visa Inc. (V) today announced the launch of USDC settlement in the United States, marking a major milestone in the company’s stablecoin settlement pilot program and strategy to modernize its settlement layer underpinning global commerce. For the first time, U.S. issuer and acquirer partners can settle with Visa in Circle’s USDC, a fully reserved, dollar-denominated stablecoin. With USDC settlement, issuers can benefit from faster funds movement over blockchains, seven‑day availability and enhanced operational resilience across weekends and holidays - without any change to the consumer card experience. Initial banking participants include Cross River Bank and Lead Bank, which have started settling with Visa in USDC over the Solana blockchain. Broader availability in the U.S. is planned through 2026. Additionally, Visa is a design partner for Arc, a new Layer 1 blockchain d
Volante Technologies Customers Successfully Navigate Critical Regulatory Deadlines for EU SEPA Instant and Global SWIFT Cross-Border Payments16.12.2025 10:00:00 CET | Press release
PaaS leader ensures seamless migrations and uninterrupted payment operations Volante Technologies, the global leader in Payments as a Service (PaaS), today announced it has successfully upgraded its clients to meet the latest SEPA Instant Payments Regulation (IPR) and SWIFT SRG 2025 mandate, which came into effect October 9th and November 22nd, 2025, respectively. This announcement follows the major FedISO upgrade in July, which shifted trillions of dollars in payments to the new ISO 20022 messaging format. SEPA IPR is a significant European milestone, requiring payments to be made within 10 seconds and at any time of day, throughout the year. Adoption was mandatory and Eurozone banks were compelled to meet strict deadlines, with January 9th, 2025 the deadline for receiving incoming instant payments and October 9th the deadline for sending outgoing instant payments. The latest deadline impacted more than 700 banks across Europe, with non-compliance penalties reaching at least 10% of an
TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth16.12.2025 09:05:00 CET | Press release
TreeFrog Therapeutics, a French biotech focused on bringing regenerative medicine to millions through their proprietary cell technology, C-Stem™ is delighted to announce the appointment of skilled biotech leader, Mark Rothera, as Chief Executive Officer and Board member. He succeeds Frédéric Desdouits, who is stepping down after five years in the role. In the new leadership configuration, co-founders Kévin Alessandri and Maxime Feyeux will transition from daily operations to focus on their roles on the Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215145193/en/ Mark Rothera, CEO TreeFrog Therapeutics Elsy Boglioli, Chair of the Board of TreeFrog Therapeutics, commented “On behalf of the Board, we are delighted to welcome Mark to TreeFrog. His 30+ years of biopharma leadership, including most recently, three biotech CEO roles in gene therapy and biologics, will be invaluable as we advance our Parkinson’s and liver
RoslinCT and Ayrmid Ltd. Announce Expansion of Strategic Partnership to Manufacture Omisirge® (omidubicel-onlv) for Second FDA-Approved Indication in Severe Aplastic Anemia (SAA)16.12.2025 09:00:00 CET | Press release
RoslinCT is performing technology transfer and will support commercial manufacture of Omisirge® for an additional indication following successful clinical trialsOmisirge® now FDA-approved for an expanded patient population in hematologyRoslinCT continues to support and advance multiple cell therapy projects at its Hopkinton, MA facility Ayrmid Ltd., the parent company of Gamida Cell Inc., a pioneering cell therapy company transforming cells into powerful therapeutics, and RoslinCT, a global leader in cell and gene therapy contract development and manufacturing, today announced the expansion of their strategic partnership to include the execution of a commercial supply agreement to support production of Omisirge® (omidubicel-onlv). Following positive clinical trial results, Omisirge® has received FDA approval for a second indication, broadening its use in the treatment of hematology patients. Under the commercial supply agreement, RoslinCT will complete technology transfer and support c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
